Semaglutide is a powerful medication that plays a key role in managing type 2 diabetes and obesity
The scientific question is whether these claims are supported by human outcomes, not just by theory, animal research, or peptide-market positioning
The American Heart Association suggests ~3,400 mg/day for men, ~2,600 mg/day for women
Tirzepatide is administered as a once-weekly subcutaneous injection, with dosing typically initiated at 2.5 mg and gradually titrated upward every four weeks to minimize gastrointestinal adverse effects
Allow the initial healing response to establish before introducing repetitive Achilles loading
Meaningful body composition changes typically develop over three to six months as dosing is progressively increased